World Monitor Magazine WM_November_2019_web | Page 41

EXPERT OPINION
Scientific innovation has surged during the past five years
Number of late-stage pipeline products by therapeutic drug class, 2009-2018
3 000
2 500
2 000
1 500
1 000
500
0
2009
2010
2011
2012
2013
2014
2015
2016
2017
Oncology Infectious Diseases* Neurology - Other/Behavioral GI Products
Pain Dermatology Immunology Endocrinology
Vaccines Nervous System Disorders All Others Year 2009 (2091) 2018 (2891)
Endocrinology 5% (108) 4% (110)
Immunology 4% (76) 6% (165)
Dermatology 5% (96) 6% (161)
Pain 5% (108) 6% (162)
GI products 4% (87) 6% (179)
Neurology –
Other/Behavioral 7% (137) 8% (223)
Infectious
diseases 7% (144) 7% (188)
Oncology 24% (493) 29% (849)
2018
Source: IQVIA Institute, The Changing Landscape of Research and Development, Apr 2019
12
IQVIA Russia Customer Meeting 091719
The world community is now working
on two issues of the healthcare system:
patient access to advanced diagnostic
and treatment methods, including drugs,
and lower healthcare system costs. What
changes do you see in Kazakhstan, how
much do they reflect global trends and
what do you expect to see further in the
pharmaceutical market?
Is it necessary to reduce costs? I wouldn’t
say so. I think that the main challenge
is the effective management of the
healthcare system. And these are the
problems of all countries: the availability
of developed infrastructure, networks of
clinics, the qualifications of doctors, their
training, a network of pharmacies, and
correct pricing.
As I have already mentioned, Kazakhstan
became one of the first countries in
Central Asia to use modern methods
for Health Technology Assessment
(HTA). HTA is not only an estimate of
direct costs but also an assessment of
the impact of treatment on the entire
environment. Thus, the price of medicine
is not an essential factor. We need to
use a holistic approach to calculate. One
needs to think how much the medicine
costs, how much the medical expenses
to treat one patient, how long the
treatment lasts, how many relapses
there can be if the disease is chronic,
how it affects the patient’s quality of life
and how it will affect the patient’s family,
his ability to work, his contribution to the
development of society and the state.
Having this method of assessment in
hand, the government can look at and
accept treatment, not based solely on the
price of the medicine, but looking at the
procedure generally and strategically. It
will help to determine whether or not
it’s worth investing now more and more
expensive to reduce costs in the future,
getting the most critical outcome – a
healthy citizen. Besides, the quality of life
in society will get much higher. A lot of
advanced countries use these methods
and follow trends, and Kazakhstan is
not an exception. We have excellent
specialists who work in this direction.
I believe that with an insurance system,
we can also improve the effectiveness
of the healthcare system, providing an
evident understanding of the cash flows
of both the state and people – how much
to pay in taxes, how these funds spent
and where they go. It s a form of mutual
insurance, which is quite understandable,
and a big plus is that this type of
insurance becomes attractive, since any
person with an illness will be able to
get the necessary services, diagnostics
and services at the expense of Fund of
Medical insurance.
The use of HTA, the introduction of
compulsory social health insurance
supported by EUROBAK
39